Loading
A phase 2 trial of Pentostatin, Rituximab and Bendamustine in Hairy cell leukaemia, run by National Cancer Institute (NCI), active and no longer recruiting.
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia is a phase 2 interventional study registered as NCT01059786 by National Cancer Institute (NCI), with 69 participants planned, started 2010-07-01 and due to reach its primary completion in 2022-12-15. Interventions recorded: Pentostatin, Rituximab, Bendamustine, Acetaminophen, Diphenhydramine, Epinephrine, Antihistamines, Corticosteroids, Bronchodilators, Intravenous (IV) Saline. Conditions recorded: Hairy Cell Leukemia.
Linked to the drug Pentostatin because the registry names it among its interventions and Hairy cell leukaemia among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pentostatin, Rituximab and the tag pipeline.
Shares Pentostatin and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/